Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases
- 1 December 1998
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 5 (8) , 706-712
- https://doi.org/10.1007/bf02303481
Abstract
Background: Although the survival benefit of hepatic resection for colorectal metastasis has been established, some controversy remains regarding the significance of adjuvant chemotherapy after hepatic resection. Methods: One hundred thirty-two consecutive patients who had liver resection for colorectal metastasis at our hospital between 1980 and 1997 were studied. After curative hepatic resection, 37 patients underwent systemic chemotherapy, administered orally or intraportally. Forty patients had no adjuvant chemotherapy. The chemotherapeutic agents used for oral administration were uracil and Tegafur or Tegafur alone. Mitomycin C (MMC) or 5-FU was used for IV chemotherapy. Combinations of 5-FU/leucovorin or MMC/5-FU (doxorubicin) were used for regional chemotherapy. Univariate and multivariate analyses were applied to test the significance of adjuvant chemotherapy for patient survival or disease-free survival. Results: Overall 5-year survival was 42.2% (95% CL: 31.2%, 53.2%). Among the possible prognostic factors studied, univariate analysis showed a significant difference in survival based on the number of tumors and lymph node metastases in the hepatic hilum. There was a significant difference in disease-free survival based on adjuvant chemotherapy and lymph node metastasis. The multivariate analysis for patient survival selected four prognostic factors (P<.05), including adjuvant chemotherapy, lymph node metastasis, disease-free interval, and tumor size. The multivariate analysis for disease-free survival selected adjuvant chemotherapy, lymph node metastasis, and disease-free interval as significant factors. The most common recurrence site was remnant liver, regardless of adjuvant chemotherapy. Conclusions: Adjuvant chemotherapy significantly improved survival and disease-free survival after hepatic resection for colorectal metastases. It did not decrease recurrence rate in the remnant liver.Keywords
This publication has 27 references indexed in Scilit:
- Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastasesBritish Journal of Surgery, 1997
- UFT® Modulated with Leucovorin in Advanced Colorectal Cancer: Oncopaz ExperienceOncology, 1997
- Reappraisal of Hepatic Arterial Infusion in the Treatment of Nonresectable Liver Metastases From Colorectal CancerJNCI Journal of the National Cancer Institute, 1996
- Pattern of recurrence after hepatic resection for colorectal metastasesBritish Journal of Surgery, 1993
- Perioperative Blood Transfusion and Determinants of Survival After Liver Resection for Metastatic Colorectal CarcinomaAnnals of Surgery, 1992
- Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinomaThe Lancet, 1992
- Metabolism of Tegafur in Rat Liver Observed by in vivo19F Magnetic Resonance Spectroscopy and ChromatographyJapanese Journal of Cancer Research, 1992
- Hepatic resection for colorectal liver metastasis. Influence on survival of clinical factors and surgery.Nihon Daicho Komonbyo Gakkai Zasshi, 1991
- Vascularization of small liver metastasesBritish Journal of Surgery, 1989
- Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma. A veterans administration lung cancer group studyCancer, 1982